NIOX Group Plc
("NIOX" or the "Company")
Change of Company name
NIOX Group plc (LSE: CIR) announces that further to announcements made on 10 August and 1 September 2022, the Company's change of name has become effective and the change of Tradable Instrument Display Mnemonic ("TIDM") from CIR to NIOX is expected to become effective from 5 September 2022. The ISIN and SEDOL numbers will remain unchanged. NIOX Group plc shares will continue to be traded on AIM.
Contacts
NIOX
Ian Johnson, Executive Chairman Tel: +44 (0) 1865 405 560
Michael Roller, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer Tel: +44 (0) 20 7496 3000
About NIOX
Our ambition is to improve the quality of life of millions of people suffering from asthma. The company is engaged in the design, development and commercialisation of medical devices for the diagnosis and management of asthma. Today our device, NIOX VERO®, is used by healthcare professionals and leading research organisations. We passionately believe in empowering everyone to manage their health at home and are developing NIOX for home use to meet this need. At present, NIOX provides products and services in around 50 countries. For more information please visit www.niox.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.